Psychedelics therapeutics biotech company Awakn Life Sciences Corp. (OTCQB:AWKNF) has signed what constitutes its first licensing partnership deal in Canada. Its counterpart is the Ontario community-based Wellbeings Pain Management and Dependency Clinic, which will begin using Awakn's ketamine-assisted therapy for patients under treatment for Alcohol Use Disorder (AUD) as a comorbidity for pain.
The terms call for Awakn to provide access to its proprietary therapeutics for AUD and training to Wellbeings practitioners and for Wellbeings to pay Awakn an annual subscription and a revenue share per treatment.
